Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2659-2671

  Pegram, Mark D ^a   Lipton, Allen ^b   Hayes, Daniel F ^b   Weber, Barbara L ^b   Baselga, Jose M ^b   Tripathy, Debu ^b   Baly, Debbie ^b   Baughman, Sharon A ^b   Twaddell, Tom ^b   Glaspy, John A ^b   Slamon, Dennis J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NEU DIFFERENTIATION FACTOR; RECOMBINANT MONOCLONAL ANTIBODY P 185; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0031903646     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2659     Document Type: Article

References (51)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
4. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993
5. Yonemura Y, Ninomiya I, Yamaguchi A, et al: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51:1034-1038, 1991
6. Berchuck A, Rodriguez G, Kinney RB, et al: Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15-21, 1991
7. Press MF, Pike MC, Hung G, et al: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: Correlation with poor prognosis. Cancer Res 54:5675-5682, 1994
8. Quenel N, Wafflart J, Bonichon F, et al: The prognostic value of c-crbB2 in primary breast carcinomas: A study of 942 cases. Breast Cancer Res Treat 35:283-291, 1995
9. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991
10. Stal O, Sullivan S, Sun XF, et al: Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16:160-168, 1994
11. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
12. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
13. Pantel K, Schlimok G, Braun S, et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424, 1993
14. Yamauchi H, O'Neill A, Gelman R, et al: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997
15. Volas GH, Leitzel K, Teramoto Y, et al: Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 78:267-272, 1996
16. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
17. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
18. Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611, 1988
19. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829-1838, 1994
20. Arteaga CL, Winnier AR Poirier MC, et al: p 185c-erhB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54:3758-3765, 1994
21. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
22. Fendly BM, Winget M, Hudziak RM, et al: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550-1558, 1990
23. Sias PE, Kotts CE, Vetterlein D, et al: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132:73-80, 1990
24. Marsigliante S, Muscella A, Ciardo V, et al: Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: Its correlation with sex steroid receptors, cathepsin D and histologic grades. Cancer Lett 75:195-206, 1993
25. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
26. Chazin VR, Kaleko M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859-1866, 1992
27. Roberts JJ, Pascoe JM: Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature 235:282-284, 1972
28. Rosenberg B: Possible mechanisms for the antitumor activity of platinum coordination complexes. Cancer Chemother Rep 59:589-598, 1975
29. Rice JA, Crothers DM, Pinto AL, et al: The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. Proc Natl Acad Sci U S A 85:4158-4161, 1988
30. Takahara PM, Rosenzweig AC, Frederick CA, et al: Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377:649-652, 1995
31. Zamble DB, Mu D, Reardon JT, et al: Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochem 35:10004-10013, 1996
32. Marshall JL, Andrews PA: Preclinical and clinical experience with cisplatin resistance. Hematol Oncol Clin North Am 9:415-429, 1995
33. Christen RD, Hom DK, Porter DC, et al: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86:1632-1640, 1990
34. Isonishi S, Jekunen AP, Hom DK, et al: Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. J Clin Invest 90:1436-1442, 1992
35. Yap HY, Salem P, Hortobagyi GN, et al: Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62:405-408, 1978
36. Ostrow S, Egorin M, Aisner J, et al: High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: Pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 3:23-27, 1980
37. Forastiere AA, Hakes TB, Wittes JT, et al: Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol 5:243-247, 1982
38. Bull T, Anderson ME, Lippman JG, et al: A phase II trial of cis-dichlorodiammine platinum II (CIS-DDP) in breast and ovarian carcinomas. Proc Am Assoc Cancer Res 19:87, 1978 (abstr 345)
39. Samal B, Vaithevicius V, Singhakowenta A: Cis-diamminedichlo-roplatinum (CDDP) in advanced breast and colorectal carcinomas. Proc Am Assoc Clin Oncol 19:347, 1978 (abstr 164)
40. Tsai CM, Chang KT, Perng RP, et al: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901, 1993
41. Tsai CM, Yu D, Chang KT, et al: Enhanced chemoresistance by elevation of p185new levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 87:682-684, 1995
42. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993
43. Pegram MD, Finn RS, Arzoo K, et al: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-547, 1997
44. Felip E, Del Campo JM, Rubio D, et al: Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75:2147-2152, 1995
45. Reese D, Arboleda J, Twaddell J, et al: Effects of the 4D5 antibody on HER-2/neu heterodimerization with other class I receptors in human breast cancer cells. Proc Am Assoc Cancer Res 37:51, 1996 (abstr 353)
46. Klapper LN, Vaisman N, Hurwitz E, et al: A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-2109, 1997
47. Pegram MD, Baly D, Wirth C, et al: Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of a humanized anti-HER2 antibody. Proc Am Assoc Cancer Res 38:602, 1997 (abstr 4044)
48. Hsu S, Pegram M, Pietras R, et al: Therapeutic advantage of chemotherapy drugs in combination with recombinant, humanized anti-HER-2/neu monoclonal antibody (rhuMAb HER-2) against human breast cancer cells and xenografts with HER-2/neu overexpression. Proc Basic Clin Aspects Breast Cancer: A special conference of the Am Assoc Cancer Res, Keystone, CO, March 7-12, 1997 (abstr A-39)
49. Pegram MD, Pietras RJ, Slamon DJ: Monoclonal antibody to HER-2/neu gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells. Proc Am Assoc Cancer Res 33:442, 1992 (abstr 2639)
50. Lopez AM, Pegram MD, Landaw EM, et al: Models to assess combination therapy interactions: Optimal timing of anti-HER-2 antibody and doxorubicin in breast cancer. Proc Am Assoc Cancer Res 38:605, 1997 (abstr 4061)
51. Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs, (submitted. 1997).